Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Feinstein Institute Presents Inaugural Ross Prize at New York Academy of Sciences

Dr. Dan R. Littman will receive the inaugural Ross Prize in Molecular Medicine for his contributions to the fields of immunology and virology.

Published June 14, 2013

NEW YORK, June 14, 2013—On Monday, June 24, the New York Academy of Sciences will host Translating Immunology Discoveries into Therapies: Inaugural Ross Prize in Molecular Medicine. Renowned immunologist Dan R. Littman, MD, PhD, will receive the inaugural Ross Prize in Molecular Medicine for his early discoveries and ongoing research to better understand viral, immune, and inflammatory diseases. The Ross Prize was established by the Feinstein Institute for Medical Research and Molecular Medicine.

"The Ross Prize in Molecular Medicine was conceived to recognize scientific advances and to honor people whose discoveries change the way medicine is practiced," says Kevin J. Tracey, MD, president of the Feinstein Institute.

According to the prize committee, Dr. Littman is an active investigator who produces innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine.

"It is a great honor for me to receive this prize, as it recognizes the importance of basic research in creating opportunities to advance our understanding of immune system-related diseases, which have a very large impact on our society," says Dr. Littman. "There is growing consensus that inflammatory processes have central roles in diseases that affect many physiological processes, and I thank the Feinstein Institute and Molecular Medicine for recognizing this exciting area of research."

In addition to a special talk by Dr. Littman, leading scientists in immunology will discuss new insights in the mechanism of immune system function and signaling that provide clues to the prevention or treatment of autoimmune and inflammatory diseases. Yasmine Belkaid, PhD, National Institute of Allergy and Infectious Diseases, NIH, and Alexander Rudensky, PhD, Memorial Sloan-Kettering Cancer Center, will each deliver a scientific presentation.

To see the full event agenda, visit

Special Press Briefing

Following Dr. Littman's acceptance of the Ross Prize, he will deliver a summary of his research (to be presented in full later in the day), after which members of the press will have opportunity to ask questions. Members of the press are welcome to attend the acceptance lecture (11:30 AM) and press briefing (11:45 AM), or the entire event (10:30 AM–3:00 PM).

Press must RSVP to Diana Friedman (; 212.298.8645).

About the Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 5th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit


About Molecular Medicine

Molecular Medicine publishes work in the format of original research articles, review articles, editorials, commentaries and letters to the editor, covering emerging concepts in the interdisciplinary field of molecular medicine. All content is published free online without embargo. The 2011 Journal Citation Report (JCR) cites an impact factor of 3.757 for Molecular Medicine. For more information, visit


About the New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With 25,000 members in 140 countries, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at